|Bid||43.220 x 800|
|Ask||43.230 x 800|
|Day's Range||42.765 - 43.310|
|52 Week Range||41.230 - 58.370|
|Beta (3Y Monthly)||0.85|
|PE Ratio (TTM)||17.34|
|Forward Dividend & Yield||1.27 (2.98%)|
|1y Target Est||47.20|
Novo Nordisk (NOVOb.CO) is in advanced talks to acquire assets to bolster its struggling biopharma business, its chief executive said on Monday after the drugmaker announced it had hired an AstraZeneca executive to head the unit. Novo, best known for its diabetes drugs, has been looking for biopharma assets after losing out to French rival Sanofi (SASY.PA) in the chase for Belgian biotech company Ablynx (ABLX.BR) in January. Sales at Novo's biopharma unit fell 16 percent last year and the Danish drugmaker said on Monday it has hired AstraZeneca's (AZN.L) head of cardiovascular and metabolic diseases, Ludovic Helfgott, to head the business from next April.
COPENHAGEN (Reuters) - Novo Nordisk might be able to complete an acquisition within its struggling biopharma business this year, its chief executive told Reuters on Monday. "It is not always easy ...
Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.
Novartis’s (NVS) business is separated into three segments: Innovative Medicines, the prescription medicines business Sandoz, the generics business Alcon, the eye care business
As we step into the final quarter of 2018, biotech stocks have recorded double-digit gains for the year-to-date period. Will the run up continue? Stay tuned to the following events of the upcoming week. ...
GW Pharmaceuticals (GWPH) has developed prescription medicines derived from the cannabis plant for the treatment of spasticity from multiple sclerosis. Its portfolio includes clinical stage cannabinoid products focused on the treatment of neurological conditions.
Lilly's (LLY) dual GIP and GLP-1 receptor agonist demonstrates impressive reduction in blood sugar levels as well as body weight in type II diabetes patients.
How will the Donald Trump administration’s continued efforts to overhaul the tax code affect healthcare companies in coming years? For many investors, the grave uncertainty about the political playing field has led them to stay away. On top of that, the seven healthcare stocks we talk about in this article offer a wide range of products and services within the industry, and several are in niches less vulnerable to regulatory shake-ups.
The novel drug targets two key gut hormones at the same time, and could pose a threat to currently available single-hormone drugs, which form a large and growing part of Novo's business. Lilly's treatment reduced blood sugar levels in type 2 diabetes patients by up to 2.4 percent and produced an average weight reduction of up to 12.7 percent in a mid-stage study by targeting the GLP-1 and GIP hormones.
The drug showed an average reduction of as much as 12.7 percent in weight and up to 2.4 percent in blood sugar in the midstage research, Lilly said in a statement Thursday. Lilly rose 4.2 percent to $113.10 in New York before U.S. exchanges opened. The company now plans “very broad” late-stage studies in diabetes that will likely begin by early 2019 and look at different drug combinations, said Brad Woodward, senior medical director at Lilly’s diabetes unit.
GlaxoSmithKline’s (GSK) Vaccines segment includes influenza vaccines, meningitis vaccines, shingles vaccines, and established vaccines. The vaccines segment reported revenues of ~1.3 billion pounds during the second quarter of 2018, a 13% increase in YoY revenues. The growth includes a 16% increase in operating revenues offset by a 3% negative impact of foreign exchange during the quarter.
GlaxoSmithKline (GSK) has three business segments: the Pharmaceuticals segment, the Vaccines segment, and the Consumer Healthcare segment. We’ll discuss how the company’s segments performed in this article.
On September 27, Sanofi’s (SNY) closing price was $44.84, and its market capitalization was $110.7 billion. The stock rose 1.2% that day from its previous day’s closing price. It traded at its 52-week high of $50.64 on October 6, 2017. It registered its 52-week low of $37.43 on May 9, 2018. Currently, SNY stock is trading above its 50-day moving average of $42.89 as well as its 200-day moving average of $40.89.
Eli Lilly and Company (LLY) reported revenue of ~$6.4 billion in the second quarter, surpassing Wall Street analysts’ estimates for revenue in the period.
Sanofi (SNY) is a global biopharmaceutical company, headquartered in France, with a market capitalization of $110.7 billion. It offers an expansive product portfolio that offers solutions across disease segments, including multiple sclerosis, immunology, neurology, oncology, cardiovascular diseases, diabetes, vaccines, infectious diseases, and rare disease disorders.
Denmark's Novo Nordisk (NOVOB.CO) will cut around 250 jobs in the United States, a spokesman told Reuters on Friday, adding the drugmaker would also hire an as-yet undetermined number of staff to new positions. The diabetes specialist, which employs more than 42,000 people in 79 countries, has seen growth slow due to pricing pressures in the United States, where it makes about half its revenue. Novo Nordisk will next year have to pay higher rebates on U.S. healthcare scheme Medicare, the spokesman said.
Denmark's Novo Nordisk will cut around 250 jobs in the United States, a spokesman told Reuters on Friday, adding the drugmaker would also hire an as-yet undetermined number of staff to new positions. The diabetes specialist, which employs more than 42,000 people in 79 countries, has seen growth slow due to pricing pressures in the United States, where it makes about half its revenue. Novo Nordisk will next year have to pay higher rebates on U.S. healthcare scheme Medicare, the spokesman said.
Government of Quebec provides adults living with diabetes mellitus access to ultra-long-acting insulin, TRESIBA®
Ontario becomes first province to provide public funding of TRESIBA® for adults with diabetes mellitus
Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.
Novo Nordisk, the world's top maker of diabetes drugs, said on Tuesday that it will lay off 400 staff in Denmark and China as part of a broader restructuring of its research and development organisation. Novo Nordisk said in May that new U.S. legislation aimed at reining in high drug prices would cut its 2019 sales by 1-2 percent. It announced 1,000 job cuts in 2016 as competition among insulin producers increased and prices were squeezed by pharmacy benefit managers (PBMs) who administer drug programs for employers and health plans.